ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 206 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2020. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $920,681 | -28.3% | 22,401 | -18.5% | 0.03% | -32.0% |
Q1 2024 | $1,283,228 | -23.4% | 27,484 | -21.5% | 0.05% | -30.6% |
Q4 2023 | $1,674,417 | +56.2% | 35,015 | +16.5% | 0.07% | +22.0% |
Q3 2023 | $1,071,675 | -19.1% | 30,061 | +4.7% | 0.06% | -16.9% |
Q2 2023 | $1,324,208 | +3.5% | 28,706 | -10.0% | 0.07% | -10.1% |
Q1 2023 | $1,279,230 | +253.1% | 31,901 | +307.9% | 0.08% | +229.2% |
Q4 2022 | $362,301 | +14.7% | 7,820 | +2.4% | 0.02% | +4.3% |
Q3 2022 | $316,000 | -33.8% | 7,637 | -4.4% | 0.02% | -23.3% |
Q2 2022 | $477,000 | -22.7% | 7,990 | -5.9% | 0.03% | +15.4% |
Q1 2022 | $617,000 | -21.7% | 8,491 | -9.4% | 0.03% | 0.0% |
Q4 2021 | $788,000 | -20.6% | 9,372 | -14.8% | 0.03% | -21.2% |
Q3 2021 | $992,000 | -3.9% | 11,000 | +1.6% | 0.03% | -5.7% |
Q2 2021 | $1,032,000 | -30.4% | 10,827 | -16.9% | 0.04% | -38.6% |
Q1 2021 | $1,483,000 | -23.5% | 13,028 | -7.0% | 0.06% | -32.9% |
Q4 2020 | $1,939,000 | +103.2% | 14,008 | +20.7% | 0.08% | +73.5% |
Q3 2020 | $954,000 | -8.9% | 11,610 | -13.3% | 0.05% | -15.5% |
Q2 2020 | $1,047,000 | +112.4% | 13,387 | +20.7% | 0.06% | +56.8% |
Q1 2020 | $493,000 | -26.4% | 11,088 | -29.3% | 0.04% | +27.6% |
Q4 2019 | $670,000 | +14.1% | 15,679 | +14.4% | 0.03% | -3.3% |
Q3 2019 | $587,000 | -35.6% | 13,710 | -4.6% | 0.03% | -30.2% |
Q2 2019 | $912,000 | -14.6% | 14,369 | -6.7% | 0.04% | -15.7% |
Q1 2019 | $1,068,000 | +75.9% | 15,393 | +10.4% | 0.05% | +34.2% |
Q4 2018 | $607,000 | -54.2% | 13,949 | -19.6% | 0.04% | -24.0% |
Q3 2018 | $1,324,000 | +10.4% | 17,350 | +11.2% | 0.05% | +4.2% |
Q2 2018 | $1,199,000 | +41.2% | 15,603 | -6.3% | 0.05% | +41.2% |
Q1 2018 | $849,000 | +16.1% | 16,653 | +5.6% | 0.03% | +21.4% |
Q4 2017 | $731,000 | -21.4% | 15,764 | -9.7% | 0.03% | -28.2% |
Q3 2017 | $930,000 | -6.0% | 17,453 | +9.6% | 0.04% | -13.3% |
Q2 2017 | $989,000 | -14.4% | 15,920 | -6.7% | 0.04% | -13.5% |
Q1 2017 | $1,156,000 | -9.9% | 17,062 | -6.5% | 0.05% | -11.9% |
Q4 2016 | $1,283,000 | -9.5% | 18,241 | -8.7% | 0.06% | -11.9% |
Q3 2016 | $1,418,000 | +44.3% | 19,985 | -0.6% | 0.07% | +39.6% |
Q2 2016 | $983,000 | -25.4% | 20,106 | -3.3% | 0.05% | -29.4% |
Q1 2016 | $1,317,000 | -54.3% | 20,795 | -19.1% | 0.07% | -50.4% |
Q4 2015 | $2,882,000 | +17.9% | 25,691 | +1.2% | 0.14% | -1.4% |
Q3 2015 | $2,444,000 | – | 25,376 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |